Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Preliminary Effectiveness of Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Locally Confined Intermediate Risk Prostate Cancer (Focal Therapy)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04656678
Recruitment Status : Recruiting
First Posted : December 7, 2020
Last Update Posted : January 25, 2022
Philips Healthcare
Information provided by (Responsible Party):
Ardeshir Rastinehad, Northwell Health

Brief Summary:
The purpose of this research study is to determine the safety and feasibility of using the UroNav software and DynaCAD software for planning and treating prostate cancer as an add on to the already approved workflow of using ultrasound only during the cryoablation of the prostate. The software application may aid doctors in locating a prior biopsy proven cancer location from the UroNav biopsy that patients previously had and then use that information to guide the treatment.

Condition or disease Intervention/treatment Phase
Prostate Cancer Prostate Disease Device: Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance Not Applicable

Detailed Description:
This is a single-center, prospective, single arm study to evaluate feasibility of UroNAV Ablation system aided cryo-ablation treatment of low and intermediate risk, organ-confined prostate cancer. All subjects will be treated and then followed up clinically for up to 24 months to evaluate any procedure or device related adverse events as well as to assess efficacy endpoints of the study. Additional data related to quality of life of treated subjects will also be collected

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study to Evaluate the Safety and Efficacy of Focal US Guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Locally Confined Low to Intermediate Risk Prostate Cancer
Actual Study Start Date : November 25, 2020
Estimated Primary Completion Date : October 30, 2023
Estimated Study Completion Date : October 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: DynaCAD / UroNAV
This is a single arm study to evaluate feasibility of UroNAV Ablation system aided cryo-ablation treatment of low and intermediate risk, organ-confined prostate cancer. UroNav is a stereotaxic accessory for image-guided interventional and diagnostic procedures of the prostate gland. It provides 2D and 3D visualization of Ultrasound (US) images and the ability to fuse and register these images with those from other imaging modalities such as Magnetic Resonance (MR), Computed Tomography, etc. It also provides the ability to display a simulated image of a tracked insertion tool on a computer monitor screen that shows images of the target organ and the current and the projected future path of the interventional instrument. DynaCAD 5.0 is an image analysis and planning system that will provide off station, pre planning and review of interventional study data. It interfaces with the Uronav 4.0 fusion guidance system.
Device: Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance
Focal ultrasound guided cryoablation using uroNav system Version 4.0 and Dyna CAD software version 5.0.

Primary Outcome Measures :
  1. Assessment of safety of the DynaCAD /UroNAV ablation planning and guidance system aided cryo-ablation in the treatment of low-intermediate risk, localized (organ confined) prostate cancer tumors. [ Time Frame: 24 months ]
    Incidence and severity of device/treatment related complications from treatment day visit through 24 month follow up.

Secondary Outcome Measures :
  1. Assessment of tumor control achieved by treatment. [ Time Frame: 24 months ]
    Primary effectiveness analyses will be based on the 12-month biopsy results. Post-treatment PSA, non-perfused volume (NPV) by multi-parametric MRI, and EPIC - 26 (The Expanded Prostate Cancer Index Composite) questionnaire results through Month 24 visit will be summarized as secondary measures of effectiveness.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have documented histological or cytological evidence of tumor(s) of the prostate.
  2. Patients must be ≥ 45 years of age.
  3. Patients must be able to read, understand and sign an informed consent.
  4. Organ confined clinical T1C or clinical T2a prostate cancer that is visualized on MR imaging.
  5. Prostate cancer is diagnosed by MR image guided biopsies.
  6. Gleason Score ≤ 7; and 2 or less positive lesions on prior MR US fusion guided prostate biopsy.
  7. A non MRI visible cancer detected via systematic standard biopsy will not be considered an exclusion condition provided the non-MRI visible cancer is singularly located in the contralateral hemisphere of the prostate; is Gleason 6 cancer; and comprises no more than 6mm linear extent of cancer in a single core on standard biopsy.
  8. If any standard biopsy cores are positive on the same hemisphere of the prostate gland, they must be confirmed as likely to form a contiguous lesion with the target lesion detected on MRI and therefore be from the same location in the prostate as MR lesion was biopsied and proven to be cancerous. (e.g., Left/Right, Base, Mid Gland, Apex).
  9. Prior mpMRI results dated within 120 days prior to ablation.
  10. No metastatic disease as per NCCN guidelines ( - Bone scan indicated to r/o metastatic disease if clinical T1 and PSA > 20 or T2 and PSA > 10
  11. PSA < 15 ng/ml or PSA density < 0.15 ng/ml2 in patients with a PSA > 15 ng/ml.

Exclusion Criteria:

  1. ASA status > 3
  2. Very Low Risk Prostate Cancer based on Epstein's Criteria having a tumor <0.2 cc (AUA Guidelines 2017 pg. 9)

    GG1, PSA < 10 ng/ml, no more than two positive cores and no core > 50% involvement.

  3. Contraindications to MRI

    3.1 Claustrophobia

    3.2 Implanted ferromagnetic materials or foreign objects

    3.3 Known intolerance to the MRI or US contrast agents.

    3.4 Severely abnormal coagulation (INR>1.5)

  4. Patients with unstable cardiac status including:

    4.1 Unstable angina pectoris on medication

    4.2 Patients with documented myocardial infarction within 40 days prior to enrolment

    4.3 Congestive heart failure NYHA class IV

    4.4 Patients with unstable arrhythmia status, already on anti-arrhythmic drugs

  5. Severe hypertension (diastolic BP > 100 on medication)
  6. Severe cerebrovascular disease (multiple CVA or CVA within 6 months)
  7. History of orchiectomy, PCa-specific chemotherapy, brachytherapy, cryotherapy, Photodynamic therapy or radical prostatectomy for treatment of prostate cancer; any prior radiation therapy to the pelvis for prostate cancer or any other malignancy.
  8. Patient under medications that can affect PSA for the last 3 months prior to UroNAV Ablation system aided cryo-ablation treatment (Androgen Deprivation Treatment)
  9. Patients with lesions of Gleason 7 or greater outside the planned treatment area.
  10. Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (approximately 3 hrs.)
  11. Any rectal pathology, anomaly or previous treatment, which could change acoustic properties of rectal wall or prevent safe US probe insertion (e.g., fistula, stenosis, fibrosis, inflammatory bowel disease, etc).
  12. Any spinal pathology which can prevent safe administration of epidural/spinal anesthesia
  13. Evidence for lymph node involvement of cancer
  14. Bladder cancer
  15. Urethral stricture/bladder neck contracture
  16. Patients with incontinence demonstrated by use of more than 1 pad/day. .
  17. Active UTI
  18. Prostatitis NIH categories I, II and III.
  19. Compromised renal function
  20. Interest in future fertility
  21. Current participation in another clinical investigation of a medical device or a drug or has participated in such a study within 30 days prior to study enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04656678

Layout table for location contacts
Contact: Ardeshir R Rastinehad, DO 212-434-6580
Contact: Monica K Johnson, RN 516-734-8515

Layout table for location information
United States, New York
The Smith Institute for Urology Recruiting
Lake Success, New York, United States, 11042
Contact: Monica Johnson, RN    516-734-8515   
The Smith Institute for Urology at Lenox Hill Recruiting
New York, New York, United States, 10022
Contact: Ardeshir Rastinehad, DO    212-434-6580   
Manhattan Eye, Ear, and Throat Hospital (MEETH) Recruiting
New York, New York, United States, 10065
Contact: Ardeshir Rastinehad, DO    212-434-6580   
Sponsors and Collaborators
Northwell Health
Philips Healthcare
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ardeshir Rastinehad, Associate Professor of Urology and Radiology, Vice Chair of Urology at Lenox Hill Hospital, System Director for Prostate Cancer, Northwell Health Identifier: NCT04656678    
Other Study ID Numbers: 20-0562
First Posted: December 7, 2020    Key Record Dates
Last Update Posted: January 25, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Ardeshir Rastinehad, Northwell Health:
Prostate MRI
Focal Therapy
Focal Prostate Cancer Therapy
Prostate Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Prostatic Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site